Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Minerva Neurosciences stock | $2.95

Learn how to easily invest in Minerva Neurosciences stock.

Minerva Neurosciences, Inc
-$0.02 (-0.85%)

Minerva Neurosciences, Inc is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 11 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Minerva Neurosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NERV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Minerva Neurosciences stock price (NASDAQ: NERV)

Use our graph to track the performance of NERV stocks over time.

Minerva Neurosciences shares at a glance

Information last updated 2021-07-02.
Latest market close$2.95
52-week range$2.15 - $4.12
50-day moving average $2.85
200-day moving average $2.87
Wall St. target price$7.00
PE ratio 18.4252
Dividend yield N/A (0%)
Earnings per share (TTM) $0.13

Buy Minerva Neurosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
M1 Finance
Stocks, ETFs
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Minerva Neurosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Minerva Neurosciences price performance over time

Historical closes compared with the close of $2.95 from 2021-05-28

1 week (2021-06-28) 22.41%
1 month (2021-06-03) N/A
3 months (2021-04-05) 2.43%
6 months (2021-01-05) 24.47%
1 year (2020-07-03) N/A
2 years (2019-07-05) -56.74%
3 years (2018-07-05) 8.6
5 years (2016-07-05) 10.14

Is Minerva Neurosciences under- or over-valued?

Valuing Minerva Neurosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Minerva Neurosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Minerva Neurosciences's P/E ratio

Minerva Neurosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Minerva Neurosciences shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Minerva Neurosciences's EBITDA

Minerva Neurosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.6 million.

The EBITDA is a measure of a Minerva Neurosciences's overall financial performance and is widely used to measure a its profitability.

Minerva Neurosciences financials

Revenue TTM $41.2 million
Operating margin TTM 16.06%
Gross profit TTM $19.1 million
Return on assets TTM 4.58%
Return on equity TTM 16.52%
Profit margin 12.84%
Book value $1.06
Market capitalisation $100 million

TTM: trailing 12 months

Shorting Minerva Neurosciences shares

There are currently 3.4 million Minerva Neurosciences shares held short by investors – that's known as Minerva Neurosciences's "short interest". This figure is 0.3% up from 3.3 million last month.

There are a few different ways that this level of interest in shorting Minerva Neurosciences shares can be evaluated.

Minerva Neurosciences's "short interest ratio" (SIR)

Minerva Neurosciences's "short interest ratio" (SIR) is the quantity of Minerva Neurosciences shares currently shorted divided by the average quantity of Minerva Neurosciences shares traded daily (recently around 691511.95876289). Minerva Neurosciences's SIR currently stands at 4.85. In other words for every 100,000 Minerva Neurosciences shares traded daily on the market, roughly 4850 shares are currently held short.

However Minerva Neurosciences's short interest can also be evaluated against the total number of Minerva Neurosciences shares, or, against the total number of tradable Minerva Neurosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Minerva Neurosciences's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Minerva Neurosciences shares in existence, roughly 80 shares are currently held short) or 0.0815% of the tradable shares (for every 100,000 tradable Minerva Neurosciences shares, roughly 82 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Minerva Neurosciences.

Find out more about how you can short Minerva Neurosciences stock.

Minerva Neurosciences share dividends

We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.

Minerva Neurosciences share price volatility

Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $2.15 up to $4.115. A popular way to gauge a stock's volatility is its "beta".

NERV.US volatility(beta: 1.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 1.1092. This would suggest that Minerva Neurosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Minerva Neurosciences overview

Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc.

Frequently asked questions

What percentage of Minerva Neurosciences is owned by insiders or institutions?
Currently 3.532% of Minerva Neurosciences shares are held by insiders and 74.192% by institutions.
How many people work for Minerva Neurosciences?
Latest data suggests 11 work at Minerva Neurosciences.
When does the fiscal year end for Minerva Neurosciences?
Minerva Neurosciences's fiscal year ends in December.
Where is Minerva Neurosciences based?
Minerva Neurosciences's address is: 1601 Trapelo Road, Waltham, MA, United States, 02451
What is Minerva Neurosciences's ISIN number?
Minerva Neurosciences's international securities identification number is: US6033801068
What is Minerva Neurosciences's CUSIP number?
Minerva Neurosciences's Committee on Uniform Securities Identification Procedures number is: 603380106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site